The Role of sGC Stimulators and Activators in Heart Failure With Reduced Ejection Fraction.

Published on Sep 6, 2021in Journal of Cardiovascular Pharmacology and Therapeutics2.457
路 DOI :10.1177/10742484211042706
David Cordwin1
Estimated H-index: 1
(UM: University of Michigan),
Theodore J. Berei4
Estimated H-index: 4
(UW: University of Wisconsin-Madison),
Kristen Pogue5
Estimated H-index: 5
(UM: University of Michigan)
Over the past decade, soluble guanylate cyclase (sGC) activators and stimulators have been developed and studied to improve outcomes in patients with heart failure with reduced ejection fraction (H...
馃摉 Papers frequently viewed together
Abstract Background The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect ...
#1Justin A. Ezekowitz (U of A: University of Alberta)H-Index: 70
#2Christopher M. O'Connor (Duke University)H-Index: 149
Last. Paul W. Armstrong (U of A: University of Alberta)H-Index: 130
view all 15 authors...
Abstract Objectives The purpose of this study was to examine the treatment effect of vericiguat in relation to N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels at randomization. Background Vericiguat compared with placebo reduced the primary outcome of cardiovascular death (CVD) or heart failure hospitalization (HFH) in patients with HF with reduced ejection fraction (HFrEF) in the VICTORIA (A Study of Vericiguat in Participants With Heart聽Failure With Reduced Ejection Fraction) tria...
#1Paul W. Armstrong (U of A: University of Alberta)H-Index: 130
#2Carolyn S.P. Lam (NUS: National University of Singapore)H-Index: 80
Last. Javed Butler (UMMC: University of Mississippi Medical Center)H-Index: 33
view all 18 authors...
Importance Patients with heart failure and preserved ejection fraction (HFpEF) are at high risk of mortality, hospitalizations, and reduced functional capacity and quality of life. Objective To assess the efficacy of the oral soluble guanylate cyclase stimulator vericiguat on the physical limitation score (PLS) of the Kansas City Cardiomyopathy Questionnaire (KCCQ). Design, Setting, and Participants Phase 2b randomized, double-blind, placebo-controlled, multicenter trial of 789 patients with chr...
#1Michele Emdin (Sant'Anna School of Advanced Studies)H-Index: 69
#2Alberto Aimo (Sant'Anna School of Advanced Studies)H-Index: 18
Last. Michele SenniH-Index: 53
view all 11 authors...
Abstract The significant morbidity and mortality associated with heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF) justify the search for novel therapeutic agents. Reduced cyclic guanosine monophosphate levels contribute to HF progression. Among molecules modulating the nitric oxide (NO)鈥揋MP鈥損hosphodiesterase (PDE) pathway, the evaluation of nitrates, synthetic natriuretic peptides (NP), and NP analogs has yielded mixed results. Conver...
#1Milton Packer (Baylor University Medical Center)H-Index: 116
#2Stefan D Anker (Baylor University Medical Center)H-Index: 1
Last. Martina Brueckmann (Baylor University Medical Center)H-Index: 1
view all 39 authors...
Abstract Background Sodium鈥揼lucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More eviden...
#1Paul W. Armstrong (U of A: University of Alberta)H-Index: 130
#2Burkert PieskeH-Index: 97
Last. Christopher M. O'ConnorH-Index: 149
view all 15 authors...
Abstract Background The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or h...
#1Salim S. ViraniH-Index: 66
#2Alvaro AlonsoH-Index: 95
Last. Connie W. TsaoH-Index: 27
view all 41 authors...
Background: The American Heart Association, in conjunction with the National Institutes of Health, annually reports on the most up-to-date statistics related to heart disease, stroke, and cardiovas...
#1John J.V. McMurray (Glas.: University of Glasgow)H-Index: 202
#2Scott D. Solomon (Brigham and Women's Hospital)H-Index: 158
Last. Jan B臎lohl谩vek (Charles University in Prague)H-Index: 12
view all 38 authors...
Abstract Background In patients with type 2 diabetes, inhibitors of sodium鈥揼lucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-ind...
Chronic heart failure (CHF) is a complex syndrome that results from structural and functional disturbances that affect the ability of the heart to supply oxygen to tissues. It largely affects and reduces the patient鈥檚 quality of life, socio-economic status, and imposes great costs on health care systems worldwide. Endothelial dysfunction (ED) is a newly discovered phenomenon that contributes greatly to the pathophysiology of numerous cardiovascular conditions and commonly co-exists with chronic ...
Cited By0
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.